Kamada Ltd. (KMDA)
| Market Cap | 409.11M -10.1% |
| Revenue (ttm) | 181.68M +8.6% |
| Net Income | 20.37M +26.8% |
| EPS | 0.35 +24.4% |
| Shares Out | 57.69M |
| PE Ratio | 20.09 |
| Forward PE | 15.53 |
| Dividend | $0.25 (3.54%) |
| Ex-Dividend Date | Mar 23, 2026 |
| Volume | 17,807 |
| Open | 7.01 |
| Previous Close | 6.96 |
| Day's Range | 6.99 - 7.13 |
| 52-Week Range | 6.50 - 9.35 |
| Beta | 0.15 |
| Analysts | Strong Buy |
| Price Target | 13.00 (+84.14%) |
| Earnings Date | Aug 12, 2026 |
About KMDA
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM f... [Read more]
Financial Performance
In 2025, Kamada's revenue was $180.46 million, an increase of 12.12% compared to the previous year's $160.95 million. Earnings were $20.20 million, an increase of 39.66%.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for KMDA stock is "Strong Buy." The 12-month stock price target is $13.0, which is an increase of 84.14% from the latest price.
News
Kamada (KMDA) Secures $50M Plasma Supply Agreement
Kamada (KMDA) Secures $50M Plasma Supply Agreement
Kamada enters $50M sales agreement to supply plasma to biopharmaceutical company
Kamada (KMDA) announced an agreement to supply plasma to a biopharmaceutical company focused on plasma-derived therapies. The new three-year agreement for the supply of normal source plasma from Kamad...
Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
REHOVOT, Israel and HOBOKEN, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
Kamada (KMDA) Presents Promising Cytogam Study Results at Global Conference
Kamada (KMDA) Presents Promising Cytogam Study Results at Global Conference
Kamada highlights Cytogam study results
Kamada (KMDA) highlighted results of an Investigator-Initiated Study recently presented at the 2026 International Society for Heart and Lung Transplant annual meeting, held in Toronto, Canada. The stu...
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated with improved clinical outcomes, supporting increased CYTOGAM utilization Findings from analyses of...
Kamada (KMDA) Receives FDA Nod for New Fluorescent Focus Inhibition Test
Kamada (KMDA) Receives FDA Nod for New Fluorescent Focus Inhibition Test
Kamada Receives FDA Approval For In-House Rabies Virus Neutralization Testing Laboratory
(RTTNews) - Kamada Ltd. (KMDA), a biopharmaceutical company specializing in plasma-derived therapies, announced that the U.S. FDA has approved its new in-house rabies virus neutralization testing labo...
Kamada gets FDA approval for Rapid Fluorescent Focus Inhibition Test laboratory
Kamada (KMDA) announced FDA approval of the company’s new in-house Rapid Fluorescent Focus Inhibition Test, or RFFIT, laboratory. The new laboratory is part of Kamada’s Quality Control laboratory netw...
Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory
REHOVOT, Israel and HOBOKEN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for r...
Kamada (KMDA) Q1 2026 Earnings Transcript
Kamada (KMDA) Q1 2026 Earnings Transcript
Kamada Q1 Earnings Call Highlights
Kamada NASDAQ: KMDA reiterated its full-year 2026 outlook after reporting first-quarter results that management said were in line with expectations, excluding a temporary shipment delay that shifted r...
Kamada Falls Short on Q1 2026: $0.07 EPS vs $0.12 Expected
Earnings Miss. Kamada Ltd. (NASDAQ:KMDA) reported Q1 2026 diluted earnings of $0.07 per share, falling short of the $0.12 consensus estimate by 41.7%. The I... The post Kamada Falls Short on Q1 2026: ...
Kamada (KMDA) Maintains 2026 Financial Projections
Kamada (KMDA) Maintains 2026 Financial Projections
Kamada (KMDA) Reports Strong Q1 Revenue Growth
Kamada (KMDA) Reports Strong Q1 Revenue Growth
Kamada (KMDA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Kamada (KMDA) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street e...
Kamada Releases Q1 2026 Financial Results
Kamada Ltd. The post Kamada Releases Q1 2026 Financial Results first appeared on Alphastreet .
Kamada Earnings Call Transcript: Q1 2026
Q1 2026 results were solid, with revenues of $42.5M and net income of $4.1M, despite a shipment delay. Annual guidance of $200–$205M in revenue and $50–$53M adjusted EBITDA was reiterated, supported by strong product demand and expansion in plasma and biosimilars.
Kamada Earnings release: Q1 2026
Kamada released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Kamada reports Q1 EPS 7c, consensus 12c
Reports Q1 revenue $45.24M vs. $44.02M last year. “Our operational and financial performance in 2026 is off to a solid start, with first quarter revenues and adjusted EBITDA in line…
Kamada backs FY26 revenue view $200M-$205M
backs Fy26 adjusted EBITDA view $50M-$53M. The company said, “Kamada (KMDA) is reiterating its 2026 annual financial guidance of total revenues in the range of $200 million to $205 million…
Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year
Q1-2026 Revenue of $45.2 Million, up 3% Year-over-Year; Adjusted EBITDA of $11.6 Million, representing a Robust 26% Margin of Revenues ; Net Income of $4.1 Million, up 4% Year-over-Year Underlying Dem...
Stay Ahead of the Game With Kamada (KMDA) Q1 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of Kamada (KMDA) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some o...
Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
REHOVOT, Israel and HOBOKEN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
Significant Move: Lilach Payorski Invests $80K In Kamada Stock Options
Disclosed in a recent SEC filing, Lilach Payorski , Board Member at Kamada (NASDAQ: KMDA), made a strategic move by acquiring company stock options on April 9,. What Happened: Uncovered in a Form 4 f...